The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | 1L NALIRIFOX in advanced or metastatic PDAC
Zev A. Wainberg, MD, Msc, UCLA School of Medicine, LA, CA, discusses findings of a Phase I/II study evaluating the safety and efficacy of first-line (1L) liposomal irinotecan + oxaliplatin + 5-fluorouracil + leucovorin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma (mPDAC). First-line NALIRIFOX for patients with locally advanced/mPDAC was generally manageable and tolerable, and a randomized, controlled Phase III study is underway. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
